MediWound Ltd. - Ordinary Shares (MDWD) News
Filter MDWD News Items
MDWD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MDWD News Highlights
- MDWD's 30 day story count now stands at 5.
- Over the past 23 days, the trend for MDWD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and SAFE are the most mentioned tickers in articles about MDWD.
Latest MDWD News From Around the Web
Below are the latest news stories about MEDIWOUND LTD that investors may wish to consider to help them evaluate MDWD as an investment opportunity.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmyAwarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound an additional $6.7 million i |
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial LoadsResults show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridementYAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with |
MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 26% As Investors Are Less Pessimistic Than ExpectedMediWound Ltd. ( NASDAQ:MDWD ) shareholders would be excited to see that the share price has had a great month, posting... |
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
MediWound (NASDAQ:MDWD) investors are sitting on a loss of 75% if they invested five years agoWhile not a mind-blowing move, it is good to see that the MediWound Ltd. ( NASDAQ:MDWD ) share price has gained 14% in... |
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
MediWound Reports Third Quarter 2023 Financial Results and Provides Company UpdateNexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Operating cash runway through profitability Conference call on Tuesday, November 21 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therape |
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerYAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. “We are delighted to welcome Shmulik, a distinguished ind |
MediWound to Report Third Quarter 2023 Financial ResultsConference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern TimeYAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 on Tuesday, November 21, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to d |
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric PatientsThe label expansion will solidify NexoBrid’s position in the EU as a safe and effective non-surgical treatment for burn patients of all agesYAVNE, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change |